AVALO THERAPEUTICS INC (AVTX)

US05338F3064 - Common Stock

17.23  +1.29 (+8.09%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
5.4M
-19.40%		18.05M
234.26%		1.924M
-89.34%		1.224M
-36.38%
EBITDA
YoY % growth
-80.47M
-77.05%		-37.27M
53.68%		-23.286M
37.52%		N/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
-82.13M
-73.67%		-37.44M
54.41%		-23.444M
37.38%		-13.056M
44.31%
Operating Margin
-1,520.93%-207.42%-1,218.50%-1,066.67%
EPS
YoY % growth
-9.96
5.68%		-253.04
-2,440.56%		-488.22
-92.94%		-17.14
96.49%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS
Q2Q % growth		-1.20
99.41%
Revenue
Q2Q % growth
EBITDA
Q2Q % growth		N/AN/AN/AN/A
EBIT
Q2Q % growth		-4.794M
45.46%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 -116.22
53.44%		-4.90-111.32-2,273.67%
Q3 2023
Q2Q % growth		 -26.40
-7,864.71%		-269.28242.8890.20%
Q2 2023
Q2Q % growth		 -141.60
-10,160.87%		-195.8454.2427.70%
Q1 2023
Q2Q % growth		 -204.00
-8,400.00%		-237.4633.4614.09%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 571K
-36.56%		306K265K86.60%
Q3 2023
Q2Q % growth		 240K
-98.39%		1.02M-780K-76.47%
Q2 2023
Q2Q % growth		 640K
-37.86%		510K130K25.49%
Q1 2023
Q2Q % growth		 480K
-58.97%		1.02M-540K-52.94%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS75.42% 75.42% 0% 0%
Revenue-100% -100% 0% 0%